Daniel Orlando

Daniel Orlando is the Chief Executive Officer of Alcresta Therapeutics. He joins the team with more than 18 years of executive management and corporate development experience leading organizations through rapid growth in the development, manufacturing and commercialization of therapeutics and biologics. Prior to joining Alcresta Therapeutics, Daniel was most recently the Chief Operating Officer of Vericel Corporation, an autologous cell therapy company, which purchased the cell therapy and regenerative medicine business unit from Sanofi Genzyme. During his tenure, he led every function at Vericel, most recently, Sales, Marketing, Manufacturing, Engineering, and Research & Development. Before joining Vericel, Daniel was one of Takeda North America’s early employee’s and held executive positions in Business Development, Marketing, and Sales as well as similar developmental roles at Abbott Laboratories. Daniel holds a BA in Economics with Honors from the University of Florida and an MBA from Florida Atlantic University.